InMode Ltd. (NASDAQ:INMD - Get Free Report)'s share price reached a new 52-week low on Friday . The stock traded as low as $13.67 and last traded at $13.78, with a volume of 482347 shares traded. The stock had previously closed at $14.05.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on INMD. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. BTIG Research cut shares of InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. UBS Group cut their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Barclays cut their price target on shares of InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Finally, Jefferies Financial Group cut their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a report on Monday, April 14th. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $18.54.
View Our Latest Stock Report on INMD
InMode Stock Performance
The company has a market cap of $844.47 million, a PE ratio of 5.69 and a beta of 1.98. The stock's 50 day moving average price is $14.66 and its 200-day moving average price is $16.75.
InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The business had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. During the same period last year, the company posted $0.32 EPS. InMode's revenue for the quarter was down 3.0% on a year-over-year basis. On average, analysts anticipate that InMode Ltd. will post 1.75 EPS for the current year.
Institutional Investors Weigh In On InMode
Several institutional investors have recently added to or reduced their stakes in INMD. Strs Ohio purchased a new stake in shares of InMode in the 1st quarter worth about $254,000. Acadian Asset Management LLC lifted its position in shares of InMode by 6.6% in the 1st quarter. Acadian Asset Management LLC now owns 556,413 shares of the healthcare company's stock worth $9,858,000 after purchasing an additional 34,623 shares during the period. Focus Partners Wealth lifted its position in shares of InMode by 31.8% in the 1st quarter. Focus Partners Wealth now owns 227,959 shares of the healthcare company's stock worth $4,044,000 after purchasing an additional 54,948 shares during the period. Fred Alger Management LLC lifted its position in shares of InMode by 75.7% in the 1st quarter. Fred Alger Management LLC now owns 543,750 shares of the healthcare company's stock worth $9,646,000 after purchasing an additional 234,285 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in shares of InMode by 234.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company's stock worth $19,935,000 after purchasing an additional 788,157 shares during the period. Hedge funds and other institutional investors own 68.04% of the company's stock.
About InMode
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Stories
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
